This study examined the prevalence of vitamin K deficiency in children pre-bone marrow transplantation (BMT). Vitamin K status was measured by the PIVKA-II assay and prothrombin times. Blood samples were obtained before vitamin-containing TPN was infused. Results indicated that eight of 26 patients (31%) were vitamin K deficient; four cases were attributed to drug antagonism (phenytoin) and four were due to inadequate vitamin K intake, synthesis or malabsorption. Only one patient had a prolonged prothrombin time. Prothrombin time, in our study, is shown to be an ineffective screening tool to determine vitamin K status. All patients receiving phenytoin and chemotherapy are at increased risk of vitamin K deficiency. Bone Marrow Transplantation (2006) 37, 151-154.
Introduction
Vitamin K deficiency has been shown to occur in bone marrow transplant (BMT) [1] [2] [3] [4] and oncology [5] [6] [7] patients increasing their risk of serious hemorrhage. The etiology of vitamin K deficiency is most often multifactorial, but usually results from drug antagonism, liver dysfunction, fat malabsorption, anorexia and/or inadequate nutrient intake. The Hospital for Sick Children (HSC) is Canada's largest pediatric BMT center, performing 70 transplants each year. Approximately 80% of the transplants performed at HSC are for malignant diseases therefore most patients have been exposed to previous courses of chemotherapy. Chemotherapy is often associated with anorexia, nausea and vomiting, and may cause epithelial damage to the gastrointestinal tract resulting in fat and fat-soluble vitamin malabsorption. One or more of these factors may increase the risk of vitamin K deficiency developing prior to BMT. Thus, the purpose of our study was to determine the occurrence and cause of vitamin K deficiency in children prior to BMT.
Materials and methods

Patient population
All patients admitted to The HSC's BMT Unit for autologous or allogeneic marrow transplantation between 1996 and 1997 were asked to participate in the study. Any patient who received TPN within a week prior to the blood samples being drawn was excluded from the study as the TPN solutions were supplemented with vitamin K. The study was approved by The HSC's Research Ethics Board.
Baseline assessment
After consent was obtained, a nutritional assessment was completed which consisted of a review of concurrent medical problems; medications (including vitamin usage); height, weight and % ideal body weight; current diet; food/formula intakes and any appetite or GI problems. To determine vitamin K status, blood was sampled to determine the presence of the 'protein induced by vitamin K absence' (PIVKA-II), prothrombin time (PT) and partial thromboplastin time (PTT).
Analyses
Plasma samples were assayed using the Asserachrom PIVKA II Enzyme Immunoassay (Diagnostica Stagot) using a monoclonal antibody previously described by Motohara et al. 8 As per the product monograph, vitamin K deficiency was defined as a plasma PIVKA-II value greater than 2 ng/ml, indicating the presence of a biochemical vitamin K deficiency.
PT, although an insensitive marker of vitamin K deficiency, is the current method used at HSC to determine vitamin K status. PT was therefore included as a component of this study to determine the occurrence of vitamin K deficiency by the current detection methods. PT was measured using the one-stage Quick method. 9 An abnormal PT was defined as a PT greater than 2 s outside HSC's normal lab range of 10.5-13.5 s.
Results
Patient characteristics
Twenty-six patients participated in the study (13 females, 13 males). The mean age was 9 years (range 22 months-17.5 years). Twenty-two of 26 patients (85%) were appropriate weight for height; defined as 90-110% of their ideal body weight for height (IBW). Three of 26 patients (11%) were underweight for their height (o90% IBW) and one patient was overweight (4120% IBW). The distribution of diagnoses is described in Table 1 .
A wide variety of conditioning regimes were used based on patient diagnosis and recommended therapy at the time. Nine patients received autologous transplants and 17 had allogeneic transplants, eight from HLA-matched unrelated donors. Twelve patients were conditioned with total body irradiation, with cyclophosphamide (Cy/TBI) or etoposide (VP-16/TBI); four patients received VP-16/carboplatinum/ cyclophosphamide; five patients received busulfan-containing regimens (busulfan/cyclophosphamide (Bu/Cy)); and the remaining five patients received miscellaneous protocols.
Blood sampling occurred during or post-chemotherapy in 21 of 26 patients (81%) and five patients (19%) had blood taken pre-chemotherapy. The patients who had their blood taken pre-chemotherapy were not vitamin K deficient.
Vitamin K status
The mean PIVKA-II value was 62.6784.7 ng/ml (range 0.0-263.8). Vitamin K deficiency (PIVKA-II level 42.0 ng/ml) was identified in eight (four male, four female) of 26 patients (31%) ( Table 1) . Four of the eight vitamin-K deficient patients (50%) had received the anticonvulsant medication, phenytoin. The patient with the highest PIVKA-II value had been receiving phenytoin prior to admission to control seizures associated with a brain tumor. The other three patients received phenytoin as busulfan-induced seizure prophylaxis.
Five of 26 patients (19%) were conditioned with the Bu/ Cy protocol and received phenytoin. The effect of phenytoin was not measurable in two of the five patients on the Bu/Cy protocol because their blood samples had been obtained upon admission to hospital, prior to receiving any chemotherapy. The remaining three patients conditioned with Bu/Cy were vitamin K deficient. Phenytoin levels were not available on all patients, only those who received the liquid phenytoin suspension, therefore assessment of possible associations between phenytoin levels and vitamin K status was not possible.
There was no association between low %IBW (underweight) and vitamin K deficiency. All patients had normal baseline albumin levels peri-BMT, measured on day À10 to day þ 4, mean ¼ 37 g/l (range 33-42). Most patients were eating upon admission and three were G-tube fed. One of 26 patients had a prolonged PT (PT ¼ 15.6 s) and also had an elevated PIVKA-II level at this time (23.6 ng/ml). He did not receive phenytoin but his food intake had been markedly reduced prior to the hospital admission due to previous chemotherapy treatment. All patients in the study had normal PTT's. Of the eight vitamin K-deficient patients, 6/8 (75%) experienced bleeding peri-transplant. Mild bleeding occurred in 5/8 (two hematemesis, two blood in the stool, one mild hematuria) and significant hemorrhagic cystitis occurred in 1/8 vitamin K-deficient patients.
Seven of eight patients with elevated PIVKA-II levels pre-BMT had undetectable levels by 14 days post-BMT and the patient with the highest PIVKA-II level fell to zero after 21 days. This fall in PIVKA-II levels was likely due to the vitamin K in the TPN which was given to each of these patients.
Discussion
The prevalence of vitamin K deficiency prior to bone marrow transplantation was high at 31%. Half of those who were vitamin K deficient had received phenytoin and all patients who had blood samples drawn after receiving phenytoin were vitamin K deficient.
At HSC, phenytoin is used for 7 days to prevent seizures in patients receiving the chemotherapeutic agent, busulfan. The highest PIVKA-II value was observed in a patient who had been receiving phenytoin prior to admission due to seizures associated with a brain tumor. Phenytoin is a known vitamin K antagonist. The mechanism of action appears to be related to the induction of hepatic microsomal oxidase enzymes. 10 It is hypothesized that these enzymes increase the rate of oxidative degradation of vitamin K. An association between maternal anticonvulsant therapy and neonatal hemorrhage is well recognized. A coagulation defect, similar to vitamin K deficiency, was described in 50% of neonates exposed to phenytoin in utero.
11
Coagulation defects and vitamin K deficiency have also been identified in patients taking anticonvulsants for seizure control. Davies et al. 12 demonstrated that the mean PIVKA concentration in 16 epileptic patients on anticonvulsant treatment was significantly higher compared to controls. Tam and Myer 13 presented a case study of a girl with a seizure disorder who was taking phenytoin. After a short period of anorexia, a vitamin K-dependent coagulopathy developed and the patient experienced profuse bleeding of her gums. Following treatment with vitamin K the bleeding stopped, PT normalized and the coagulation factors returned to normal levels. In the current study, there is no obvious explanation for the four patients with vitamin K deficiency who were not taking phenytoin. All four patients were appropriate weight for height (90-100% IBW), they had no evidence of liver dysfunction and were not taking antibiotics. Their deficiency was most likely due to a combination of inadequate vitamin K intake associated with the anorexia of radiation or chemotherapy treatment. In addition, malabsorption secondary to damage to the epithelial lining of the gastrointestinal tract from radiotherapy and chemotherapy may have contributed to the vitamin K deficiency. All four patients had diagnoses associated with high nutritional risk 14 (i.e. neuroblastoma; Ewing's sarcoma; rhabdomyosarcoma), which may have contributed to the vitamin K deficiency. It is plausible that the short break between their initial chemotherapy and/or radiation and their admission for the BMT left little time to recover their nutritional status and gastrointestinal function. One of these four patients was eating very poorly prior to admission, had a prolonged PT and was treated with vitamin K. The other three patients were eating pre-BMT but the intake of vitamin K-rich foods, such as green leafy vegetables was not recorded. In another study by Conly et al., 6 poor vitamin K intake had been described during chemotherapy in adult cancer patients. Vitamin K intake was lower than the recommended daily intake during 88% of all days recorded in the Conly study.
This study has identified patients at risk of vitamin K deficiency. PT, in our study, was shown to be an ineffective screening tool to determine vitamin K status. PIVKA, although sensitive, is not routinely used in the clinical setting and coagulation factor levels are costly and can potentially be influenced by other factors in this patient population. 15, 16 In most cases, the risk of vitamin K deficiency is not considered in hospitalized patients. Nevertheless, clinical bleeding episodes can be serious and late sequelae of vitamin K deficiency. Not all children with vitamin K deficiency will develop a clinically significant bleeding episode and the incidence is quite low. However, a bleeding episode in the post-BMT period may have serious and life-threatening consequences. 17, 18 Thus, the authors suggest that those patients who are not receiving vitamin K-supplemented TPN post-BMT are at risk of vitamin K deficiency and oral vitamin K supplementation should be considered.
Results from the current study demonstrate that patients receiving long-term phenytoin treatment and chemotherapy, especially those with brain tumors, are at increased risk of vitamin K deficiency. In addition, BMT patients receiving short-term phenytoin as busulfan-induced seizure prophylaxis are also at risk of becoming vitamin K deficient. Further study is required to determine if prophylactic vitamin K supplementation would prevent deficiency among patients receiving the Bu/Cy-conditioning regime.
